Industry Analysis: SJ & JW Evans Limited

1. Industry Classification

Sector: Community Pharmacy (SIC 47730 – Dispensing chemist in specialised stores)

This classification places the company within the UK community pharmacy sector, which comprises approximately 11,500 pharmacy premises across England, Scotland, and Wales. The sector is characterised by:

• Heavy reliance on NHS contract income (typically 80-90% of revenue for dispensing pharmacies)
• Regulatory oversight by the General Pharmaceutical Council (GPhC)
• Margin pressure from NHS funding reforms and drug tariff reductions
• High fixed costs (staffing, premises, professional indemnity)
• Consolidation trends driven by multiple operators (Boots, Lloyds, Well) and growing influence of pharmacy-led groups

The company's registered address in Malvern, Worcestershire, positions it within a market town demographic – typically serving an older, NHS-dependent population base, which historically provided stable dispensing volumes.

2. Relative Performance

The financial trajectory of SJ & JW Evans Limited is deeply concerning when benchmarked against sector norms:

Critical observations:

• Catastrophic erosion of capital base: Net assets collapsed from £490,411 (2016) to £74 (2024) – a 99.98% decline. This far exceeds the margin erosion seen across the sector, where typical net asset declines have been 20-40% over comparable periods due to NHS funding constraints.
• Dormant status: The 2024 accounts explicitly state "the principal activity of the company is that of a dormant company." This represents a complete cessation of trading operations – the pharmacy is no longer dispensing.
• Accumulated losses: The £926 P&L reserve deficit against £1,000 share capital indicates the company has consumed virtually all its capital base, leaving shareholders' funds at a nominal £74.
• Going concern dependency: The accounts note reliance on "continued support of PM Hawkes Limited" – the controlling corporate shareholder. This is a significant red flag indicating the entity cannot sustain itself as a standalone operation.

3. Sector Trends Impact

Several macro and sector-specific forces have likely contributed to this outcome:

NHS Funding Pressure: The community pharmacy contractual framework has seen real-terms funding reductions of approximately 20-25% since 2015. The fixed funding envelope of approximately £2.6 billion annually has been eroded by inflation and increased volume demands, creating unsustainable margin compression for single-outlet operators.

Margin Erosion on Dispensing: Category M drug tariff adjustments have progressively reduced purchase margin on NHS dispensing, which historically cross-subsidised the front-of-shop retail operation. Many independent pharmacies have seen dispensing profit fall to £1-2 per item from historical levels of £3-5.

Workforce Costs: Mandatory pharmacist presence requirements, combined with sector-wide recruitment challenges and Agenda for Change pay pressures, have inflated staffing costs by 15-20% since 2019 – costs that cannot be recovered through NHS contract income.

Consolidation Dynamics: The sector has witnessed significant consolidation, with larger groups achieving economies of scale in purchasing, head office functions, and locum procurement. Independent operators like SJ & JW Evans Limited lack these advantages, creating a structural competitive disadvantage.

COVID-19 Impact: While pharmacies remained open during the pandemic, many incurred additional costs for PPE, staffing cover, and increased clinical services without proportionate reimbursement, further eroding thin margins.

The 2020 Anomaly: The jump in total assets to £837,341 (2020) from £332,759 (2019) and cash to £157,434 from £8,974 likely represents either property-related revaluation or, more probably, asset transfer/restructuring activity associated with the Pm Hawkes Limited relationship rather than organic trading performance.

4. Competitive Positioning

Position: Former operator, now dormant shell

The company's competitive position has effectively ceased to exist. However, understanding the trajectory is instructive:

Historical Strengths (pre-2017): - Established since 2003, providing two decades of local market presence - Pharmacist-director ownership (Philip Hawkes) aligning professional and commercial incentives - Net assets of £490,411 (2016) suggesting a previously viable business, likely including freehold property value

Current Weaknesses: - Complete cessation of trading activity - Net assets reduced to negligible levels - Dependency on parent entity for going concern viability - No retained earnings – all historical profits consumed - No cash reserves for operational restart even if desired

Ownership Structure Implications: Pm Hawkes Limited's >75% control suggests this entity was likely used as a vehicle within a wider pharmacy group structure. The two additional PSCs (Mrs Louise Vickers and Mrs Yvonne Cawley) with "significant influence or control" may represent family interests typical of independent pharmacy ownership. The appointment of D S Patel and N Nasrullah as directors (neither identified as pharmacists) alongside Philip Hawkes (pharmacist) suggests a transition from owner-operator to corporate management structure prior to dormancy.

Sector Comparison: The typical independent community pharmacy in the UK generates turnover of £600,000–£1.2 million, maintains net assets of £50,000–£200,000, and operates on EBITDA margins of 2-5%. SJ & JW Evans Limited's trajectory from net assets of nearly £500,000 to £74 represents a far more severe decline than sector averages, suggesting either significant trading losses, asset extraction, or restructuring activity associated with the broader corporate group.

SJ & JW Evans Limited represents a former community pharmacy that has experienced near-total capital erosion, declining from net assets of £490,411 in 2016 to a nominal £74 in 2024, and is now classified as dormant. While the UK community pharmacy sector has faced severe margin pressure from NHS funding constraints, rising workforce costs, and regulatory burdens – with many independents struggling – this company's decline far exceeds sector norms, likely compounded by its position within the Pm Hawkes Limited corporate structure. The entity now functions solely as a dormant shell, dependent on its parent for going concern support, and holds no meaningful competitive position within the dispensing chemist market.